Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects

Rivaroxaban and dabigatran are new oral anticoagulants that specifically inhibit factor Xa and thrombin, respectively. Clinical studies on the prevention and treatment of venous and arterial thromboembolism show promising results. A major disadvantage of these anticoagulants is the absence of an ant...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Circulation (New York, N.Y.) Ročník 124; číslo 14; s. 1573
Hlavní autori:	Eerenberg, Elise S, Kamphuisen, Pieter W, Sijpkens, Meertien K, Meijers, Joost C, Buller, Harry R, Levi, Marcel
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 04.10.2011
Predmet:	Adult Anticoagulants - antagonists & inhibitors Antidotes - pharmacology Benzimidazoles - antagonists & inhibitors beta-Alanine - analogs & derivatives beta-Alanine - antagonists & inhibitors Blood Coagulation - drug effects Blood Coagulation Factors - pharmacology Cross-Over Studies Dabigatran Double-Blind Method Endopeptidases Factor Xa Inhibitors Humans Male Morpholines - antagonists & inhibitors Partial Thromboplastin Time Prothrombin Time Rivaroxaban Thiophenes - antagonists & inhibitors Thrombin - antagonists & inhibitors Thrombin Time Young Adult
ISSN:	1524-4539, 1524-4539
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!